细胞色素P450酶2D6(CYP2D6)新变异体功能改变的分子机理与临床表型研究

批准号:
81973397
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
胡国新
依托单位:
学科分类:
临床药理
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
胡国新
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
显著的遗传多态性导致CYP2D6酶活性广泛性改变,因此产生的药代动力学变化是引起底物药物疗效个体差异的重要原因。虽然新变异不断被发现,但对应的功能研究却相对滞后;其结构和活性改变的分子机理仍不清晰。本项目组基于前期研究发现的新型CYP2D6变异体,通过酶动力学研究与基于计算机的分子对接,发现不同变异体对β受体阻断剂的酶动力学特征呈现差异,但底物与野生型蛋白的结合域相似且与血红素垂直。因此我们假设:CYP2D6酶活性口袋中与血红素垂直区域的构象改变是产生活性差别的重要原因。同时我们寻找到了携带新型变异体的受试者并明确了对应的基因型。本项目拟利用生物信息分析技术研究底物结构、变异位点与酶活性的相关性;通过结构生物学技术在分子水平阐明酶活性改变的机理;基于PK-PD模型明确新基因型的临床代谢表型。建立“基因-分子结构-临床表型”关系,为临床精准应用CYP2D6底物药物提供理论依据和数据支持。
英文摘要
The genetic polymorphisms of CYP2D6 lead to extensive change in enzyme activity. It’s the main reason that causing dramatic change in pharmacokinetic profiles and individual differences in the efficacy of substrate drug. Although novel variants of CYP2D6 are constantly being discovered, the corresponding functional studies are relatively lagging. The molecular mechanism underlies structure and activity changes are still unclear. In our previous studies, we discovered some novel CYP2D6 variants. By using enzyme kinetics study, we found that variants exhibit significant differences in enzyme kinetic profiles of β-blockers. However, these β-blockers have the similar binding domain in CYP2D6, which is perpendicular to heme. Therefore, we hypothesized that the conformational change in the vertical region above heme in the activity center of CYP2D6 is the main reason that lead to vary in activity among drugs. Meanwhile, we found the subjects carrying the new variants and identified the corresponding genotypes. This project intends to use bioinformatics technology to study the correlation among substrate structure, mutation site and enzyme activity; to elucidate the molecular mechanism of enzyme activity change at the molecular level through structural biology techniques; to define the clinical metabolic phenotype of new genotypes based on PK-PD model. A "gene-molecular structure-clinical phenotype" relationship would be established to provide theoretical basis and data support for clinically accurate application of CYP2D6 substrate drugs.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.3389/fphar.2022.985159
发表时间:2022
期刊:Frontiers in pharmacology
影响因子:5.6
作者:
通讯作者:
DOI:10.1055/a-1502-7131
发表时间:2021-06
期刊:Planta Medica
影响因子:2.7
作者:Jianchang Qian;Ying‐hui Li;Xiaodan Zhang;Daoxing Chen;Mingming Han;Tao Xu;Bingbing Chen;G. Hu-G.
通讯作者:Jianchang Qian;Ying‐hui Li;Xiaodan Zhang;Daoxing Chen;Mingming Han;Tao Xu;Bingbing Chen;G. Hu-G.
DOI:10.1111/fcp.12795
发表时间:2022-05
期刊:Fundamental & Clinical Pharmacology
影响因子:2.9
作者:Tao Xu;Nan-yong Gao;Ying‐hui Li;Ru Wang;Bingbing Chen;G. Hu;Xiaodan Zhang
通讯作者:Tao Xu;Nan-yong Gao;Ying‐hui Li;Ru Wang;Bingbing Chen;G. Hu;Xiaodan Zhang
邻苯二甲酸酯复合染毒对睾丸间质细胞及间质干细胞的毒性机制研究
- 批准号:81373032
- 项目类别:面上项目
- 资助金额:70.0万元
- 批准年份:2013
- 负责人:胡国新
- 依托单位:
国内基金
海外基金
